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Muscular-skeletal DisorDers – Patient-reported outcomes & Patient 
Preference studies
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assessMent of MeDication aDherence in rheuMatoiD arthritis 
Patients in a tertiary care hosPital
Doddapaneni S., Shetty R., Sabih I, Maddali K., Khera K.
Manipal College of Pharmaceutical Sciences, Manipal, India
Objectives: To assess the medication adherence rates and quality of life in 
Rheumatoid Arthritis (RA) patients. MethOds: RA patients admitted in the 
general medicine ward of a tertiary care hospital in Karnataka, India, during 
August to December 2013 were enrolled in the study. Demographic data of these 
patients was collected from patients’ medical records, outpatient data and by 
interviews. Patients (age≥ 18 years) with RA, irrespective of sex, fulfilling the 2010 
ACR/EULAR Classification Criteria, were enrolled in the study. Patient’s assessment 
of adherence to medication was analyzed by using Medication Adherence Report 
Scale (MARS) and physical function using the Kannada version of the Stanford 
Improved Health Assessment Questionnaire (KA-HAQ) was collected. Results: 
The mean age of 72 RA patients was 46.90 ± 12.88 years and disease durations was 
4.27 ± 5.53 years. 86% of the patients were females. Among patients, 15 (21.43%) 
received methotrexate alone and 28 (40%) received a combination therapy of 
methotrexate and hydroxychloroquine. The mean KA-HAQ score of RA patients 
measured by KA-HAQ was 2.70 ± 1.01. Scores on MARS ranged from 26 to 41 with a 
mean score of 38.65 ± 3.5. The Cronbach’s alpha for the MARS was 0.6 and KA-HAQ 
was 0.92.Using the mean cut-point 44% of 68 patients who completed the MARS 
were adherent and remaining 64% were not adherent. cOnclusiOns: In our study 
we found that 64% of the patients were not adherent to the medications which 
lead to decreased quality of life RA patients. Adherence to the medications is the 
optimal management for RA.
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Batlkham B.1, Oyunaa C.2, Odongua N.3
1School of Nursing, Health Science University of Mongolia, Ulaanabaatar, Mongolia, 2School of 
Nursing, Health Science University of Mongolia, Ulaanbaatar, Mongolia, 3School of Nursing, 
Health Science University of Mongolia, Ulaanbaatar, Mongolia
Objectives: Purpose of the study was to determine kinematic difference 
between overground and treadmill walking. MethOds: A total of 30 healthy 
men, 30 healthy female aged 19-23 participated in the study. Inclusion criteria 
in the study were that participants no low back and lower extremity pain, no 
traumatic injury and foot deformities. Participants walked at their preferred 
velocity on overground. The treadmill velocity was adjusted average velocity 
obtained in overground walking. Walking in two conditions was captured by high 
speed camera and analyzed by motion analyses software. Results: In com-
parison between treadmill and overground walking was significantly different. 
Maximum hip flexion angle (P< 0.017), maximum),maximum knee flexion (0.033)
maximum ankle dorsiflexion (P< 0.028) and maximum ankle planterflexion 
(P< 0.044) were significantly different in the two conditions. In the male, maximum 
hip flexion (P< 0.020), maximum knee flexion (P< 0.019), maximum ankle dorsi-
flexion (P< 0.018) ) were significantly different in the two conditions. For female, 
maximum hip flexion (P< 0.015), maximumankle dorsiflexion (P< 0.045), maximum 
plan terflexion (P< 0.021) were significantly different in the two conditions. 
Overground walking male of knee extension was associated with body mass 
(r= -411, p< 0.05), hip flexion was associated with body height (r= 0.433, p< 0.05). 
Overground walking female of knee flexion was associated with body mass dur-
ing (r= 0.469, p< 0.05), ankle dorsiflexion was associated with height (r= 0.443, 
p< 0.05). Treadmill walking in female, hip extension (r= -0.542, p< 0.05), knee flexion 
(r= -0.342, p< 0.05), ankle dorsiflexion (r= -0.469, p< 0.05) was associated with body 
mass.Hip extension was associated with height (r= -0.542, p< 0.05). cOnclusiOns: 
The study revealed significantly kinematic difference between overground and 
treadmill walking.
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Objectives: Patellofemoral pain syndrom is a common problem experienced 
by active adults and adolescents. Ascending stairs is one of the most painful 
activities of daily living in person with patellofermoral pain syndrome. However, 
its etiology has remained vague and is controversial. Nevertheless previous stud-
ies were reported from either the viewpoint of kinematics of the knee joint or 
hip muscle weakness, and is unclear whether hip and knee muscle weakness 
affect on knee medial displacement during physical acitvities. of the this study 
was to determine relationship between hip muscle strength and kinematics of 
the knee joint. MethOds: Forty healthy subjects participated in this study. The 
knee medial displacement was measured during a functional tests using two 
high speed cameras. Images of videos were processed using motion analysis 
software. Peak isometric muscle strengths of the following muscles were meas-
ured hip abductors, hip adductors, hip external rotators, hip internal rotators, 
knee extensors and knee flexors. Hip and knee muscle strengths were measured 
using a hand held dynamometer as isometric muscle strength referring to Katoh’s 
method. Results: Muscle strength of hip external rotators was associated with 
knee medial displacement during both single leg squatting (r= - 0.519, P< 0.001) 
and dropping (r= -0.520, P< 0.001). cOnclusiOns: The present results suggest 
that hip muscles’ strength, particularly hip external rotators’ strength are closely 
associated with knee medial displacement.
Objectives: A phase III clinical trial demonstrated the advantage of denosumab 
over zoledronic acid(ZA) in delaying the first on-study and subsequent skeletal-
related events(SREs) in patients with prostate cancer(PC). Recently, generic ZA 
became available. The purpose of this study was to examine the cost-effectiveness 
of denosumab vs. brand or generic ZA in the prevention of SREs in Kazakhstani 
patients with PC. MethOds: An excel-based Markov model was constructed with 
4-week model cycles to analyse the cost-effectiveness of the treatments from the 
perspective of Ministry of Health with a 10-year time horison for PC cohort. Direct 
costs(in 2014 tenge) included costs of drug, adverse event and SRE(pathologic frac-
ture, surgery to bone, radiation to bone, spinal cord compression) treatment. A dis-
count rate of 3% per year was applied. Effectiveness was appraised based on the 
number of SREs. The health states were defined according to SRE occurance,SRE 
history and death. The model assumed that a maximum of 1 SRE could occur in 
each cycle. Transition probabilities were derived from the relevant phase III trials. 
Results were present in the incremental total cost per SRE avoided. One-way sensi-
tivity analyses were performed to examine the robustness of the model. Results: 
Over 10-year period, denosumab incurred 103091 tenge higher costs than brand 
ZA, 677133 tenge higher costs than generic ZA, 0.58 fewer SREs per PC patient; The 
estimated incremental total direct costs per SRE avoided with the use of denosumab 
were 177743 tenge (instead of brand ZA) and 1167470 tenge (instead of generic ZA). 
Results were robust to one-way sensitivity analyses. cOnclusiOns: With assump-
tion that brand and generic ZAs are equally effective, denosumab seems to be supe-
rior alternative for brand ZA (insignificant difference in costs), and costly alternative 
for generic ZA from a perspective of Ministry of Health of Republic of Kazakhstan.
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Objectives: To evaluate the cost-utility of Infliximab plus methotrexate (MTX) com-
pared with MTX alone, in severe rheumatoid arthritis (RA) patients who were intol-
erant or inadequately responded to conventional DMARDs including MTX which is 
available in the national list of essential medicine (NLEM) in Thailand. MethOds: 
A Markov model consisting of Markov states defined by the disease activity score 
28 (DAS28) was developed to reflect the clinical assessment in the treatment of RA 
in Thailand. Markov states for remission (DAS < 2.6), low disease activity (DAS 2.6-
3.2), moderate disease activity (DAS 3.2-5.1), high disease activity (DAS ≥ 5.1), and 
dead were defined. With a cycle length of 6 months, transition probabilities were 
estimated based on ACR response in the clinical trial which was assumed to directly 
represent changes in disease severity. DAS28 was assumed to be a clinically appro-
priate proxy for utility estimation (EQ5D). Both direct and indirect costs including 
patient’s income loss were calculated under societal perspective. Data source of 
resource use are mainly based on estimation by experts. Cost and outcomes were 
discounted at 3%. One-way and probabilistic sensitivity analysis were conducted 
to test the robustness of the results. Results: Infliximab plus MTX had an ICER of 
131,867 baht per QALY gained compared to MTX alone. This falls into the range of 
acceptable ICER within 1-3 times of GDP per capita in Thailand (120,000 – 360,000 
baht per QALY gained). The probability of cost-effective for Infliximab was presented 
at 8%, 50%, and 70% at the willingness-to-pay of 120,000 baht, 240,000 baht, and 
360,000 baht per QALY gained respectively. cOnclusiOns: This model suggests, 
with its underlying assumption, that Infliximab plus MTX seems to be more cost-
effective treatment than MTX alone for Thai patients with severe RA that cannot 
be controlled by conventional DMARDs.
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Objectives: Rheumatoid arthritis (RA) is a chronic autoimmune disease charac-
terized by inflammation and destruction of the joints often resulting in a signifi-
cant impact on quality of life. There are limited studies estimating the resource 
utilization of RA patients using real-world data in Taiwan. This study aimed to 
estimate the direct health care utilization in Taiwanese RA patients. MethOds: 
We performed a retrospective database analysis using 2011 data from the National 
Health Insurance Research Database (NHIRD) in Taiwan, a claims-based database 
covering over 99% of the population. We estimated the annual incremental health 
care utilization of RA patients compared with a control cohort matched 1:4 on 
demographics and clinical covariates. Health care resources were evaluated for 
the following categories: surgeries, medications, ward use, medical materials and 
devices (MMDs), and lab tests. The percentage of patients partaking in a health 
care utilization category was calculated as the number of patients with the spe-
cific claim divided by the total number of patients in the cohort. Results: The 
total number of RA patients was 41,269. Females made up 78% of the cohort and 
the mean age was 59.4 years (SD= 15.5). The average history of RA was 5.6 years 
(SD= 2.7). When comparing RA to non-RA patients, drug utilization had some of 
the largest differences. RA patients had used traditional disease-modifying anti-
rheumatic drugs (TDMARDs), biologic DMARDs (BDMARDs), NSAIDs, and steroids 
at a rate of 70.8%, 13.2%, 64.8% and 52.8% respectively. For surgeries, lab tests, and 
MMDs, the highest incremental differences were cataract surgeries, immunology 
examination, and orthopedic replacements. cOnclusiOns: Direct health care 
utilization of RA was substantial in Taiwan. The NHIRD provides a comprehensive 
source for estimating the incremental resource utilization of RA versus non-RA 
patients. This study provides a key piece of information to estimate the burden 
of the RA illness in Taiwan.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 7 1 9 – A 8 1 3  A775
tion. cOnclusiOns: The dimensions excluding Ability of act all had the higher 
sensitivity on AIMS2-2F scale, which means overall sensitivity was better than 
SF-6D . Therefore, EQ-5D is more suitable for the evaluation of the QOL of patients 
with osteoarthritis. But the Psychological health dimension of SF-6D showed 
strong sensitivity, which prompts us Psychological problems are the important 
factors influencing the Osteoarthritis patients life quality.
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Objectives: Biologic treatments have improved outcome for immunology diseases 
in the last decades globally. However, biologic penetration in China is lower com-
pared to developed countries. This study aims to explore the willingness-to-pay 
(WTP) for biologics in immunology diseases in China by understanding decisions 
driving physicians’ prescribing behavior and patients’ payment. MethOds: Primary 
market research was done by interviewing 160 physicians with biologic experience, 
200 patients consisting of patients who have not received any biologic treatments 
before (bio-naïve), and patients with biologic experience (bio-experienced) from 
large hospitals (tier 3A) in Tier 1 and 2 cities. Patients were recruited with a diverse 
set of affordability as measured by household incomes. Results: The results show 
that patients rely on physicians for treatment recommendation. For rheumatoid 
arthritis, ankylosing spondylitis, and psoriasis, the top four factors driving physi-
cian’s recommendation are drug cost, patients’ ability-to-pay, safety of treatment 
and efficacy of treatment. For Ulcerative Colitis (UC) and Crohn’s Disease (CD), the 
top four factors were safety, efficacy, patients’ affordability followed by drug cost. 
The difference in pattern for UC and CD is likely attributed to the more severe 
nature of these diseases. Other factors such as injection frequency and mode of 
administration ranked lower for all indicators. cOnclusiOns: Patients interview 
results show that ≈60% of bio-naïve patients were rejected biologic treatment due 
to cost; ≈30% of bio-experienced patients stopped biologic treatments due to cost. 
This confirms that affordability considerations do limit the potential benefit that 
biologic treatments can provide. Interestingly, ≈30% of bio-experienced patients 
have stopped biologic treatment as it was perceived that treatment course was 
completed. This could be attributed to how physicians perceive biologics to be used. 
While affordability limits biologic penetration in auto-immune diseases in China, 
there are other considerations e.g. the severity of diseases and physician perception 
of treatment paradigm.
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Objectives: Use of innovative medicines in oncology and immunology is relatively 
lower in China compared to developed countries. This study aims to explore the 
willingness-to-pay (WTP) for these two therapeutic areas by understanding decisions 
driving physicians’ prescribing behavior and patients’ payment in immune diseases 
(rheumatoid arthritis, ankylosing spondylitis, and psoriasis) and oncology (prostate 
cancer). MethOds: For immunology, primary market research was done by inter-
viewing 160 physicians with biologic experience, 200 patients consisting of patients 
who have not received any biologic treatments before (bio-naïve), and patients with 
biologic experience (bio-experienced). For oncology, 50 physicians and 40 patients 
were recruited. All physicians and patients were recruited from large hospitals (tier 
3A) from Tier 1, 2 cities. Patients were recruited to represent a diverse set of afford-
ability. Results: The results show that patients rely on physicians for treatment 
recommendation. For rheumatoid arthritis, ankylosing spondylitis, and psoriasis, the 
top four factors driving physician’s recommendation are drug cost, patients’ ability-
to-pay, safety of treatment and efficacy of treatment. For Ulcerative Colitis (UC) and 
Crohn’s Disease (CD), the top four factors were safety, efficacy, patients’ affordability 
followed by drug cost. The difference in pattern for UC and CD is likely attributed to 
the more severe nature of these diseases. Other factors such as injection frequency 
and mode of administration ranked lower for all indicators. For oncology, the top 
factors driving physician prescription are efficacy (overall survival, progression-free 
survival) followed by safety and tolerability. Patient affordability and drug cost are 
ranked much lower. Similarly, from patients interview results, efficacy was rated 
more important than cost as a factor driving willingness-to-pay. cOnclusiOns: 
Observations from these two therapy areas show that cost and affordability are the 
top considerations when the diseases are less severe. For severe diseases and life-
threatening diseases, efficacy and safety of the drug are rated more than drug cost.
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stakeholDer eviDence requireMents anD Price exPectations for 
BiosiMilars in three asian Markets
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Objectives: Between 2011 and 2015, 32 biologics valued at more than $55 bil-
lion are expected to lose patent protection across the world (Datamonitor 2011). 
The biologics patent cliff has presented a huge opportunity for biosimilar manu-
facturers. In the context of this growing biosimilars market, this research aimed 
to investigate the regulatory environments and the evidence (clinical, economic 
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Objectives: To observe the clinical efficacy and economic value of Qin Xi-tong(QXT) 
during the long-term treatment for patients of RA. MethOds: Caulis Sinomenii(CS) 
has been recognized as an effective medicinal plant for arthritis. The Fifth Hospital 
of Xi’an developed water extract from CS to a novel kind of drug naming QXT. RA was 
diagnosed in 200 patients referred to Department of Rheumatology. All the patients 
were classified according to their different areas. They were respectively evaluated 
by the score of VAS, DAS28 and the response rates of ACR20/70 .We also follow up 
the patients for the usage rate, treatment compliance and satisfaction of QXT. We 
count the cost of patients and the income of self-made chinese traditional medicine 
in our hospital to measure the economic value of QXT. Results: We found that: 1) 
There were 140 out of 200 patients who were from 14 provinces of China with RA 
using QXT.2. Percentage of the satisfaction and compliance with the treatment of 
QXT+MTX group were higher than MTX group, satisfaction rates (94.2% vs. 67.1%, 
X2= 11.7, P< 0.01) ,compliance rates (91.4% vs. 62.9%, X2= 16.2, P< 0.01) , respectively. 
3)statistical result of year 2 showed : Compared with pretherapy,QXT+ MTX group 
scored significantly lower of VAS, while achieving higher level of ACR20 and ACR70 . 
4)QXT was safe and well tolerated in this trial, difference of adverse events was not 
statistically significant. 5)The statistics showed the mean cost for QXT only occupied 
9.2%(78/856)of patient’s expenses for the treatment of RA. cOnclusiOns: It is the 
first time to study the economic value of QXT in a randomized clinical trial for 2 
years. QXT+MTX could contribute to the higher clinical remission rates of patients 
with RA. It is worth noting that Chinese patients with RA was much better satisfied 
and complying with QXT which is actually consistent with our clinical practice.
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care neeDs for rheuMatoiD arthritis froM Patient PersPectives:  
a qualitative stuDy froM singaPore general hosPital
Xin X., Thumboo J.
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Objectives: This study aims to identify the care needs for rheumatoid arthritis (RA) 
from patient perspectives. MethOds: One-on-one in-depth interviews were con-
ducted with selected patients with RA in March 2014 in Singapore General Hospital 
as part of a larger ongoing study. The interviews were performed by a trained soci-
ologist following an interview guide allowing free probes. Each Interview lasted for 
20-60 minutes. 16 interviews were audio-recorded and transcribed with written 
consent from the patients. Notes were taken for the three unrecorded interviews. 
The transcripts and notes were analysed using NVivo 10 to identify major areas 
of patient-reported care needs. Results: 19 patients (11 Chinese, 2 Malays, and 6 
Indians; 17 females; age: 25-67 years; median educational level: higher secondary 
school) with 1-38 years of RA were interviewed. 15 had accepted that they would 
need lifelong RA medication; three were still testing if they could live without medi-
cation through self-experimentation; and one was in denial of the diagnosis. In 
additional to medical treatment, three other areas of care needs were identified: 
first, the need for knowledge about RA and its self-management (n= 17) ; second, 
the need for peer support to learn “how other people live with RA” (n= 11); and 
third, the need for psycho-emotional support to manage the emotional problems 
accompanying RA diagnosis (n= 9). These needs were most acute upon diagnosis 
and became less important once the patient had established new normality of life 
after having RA (e.g. avoiding things one cannot do due to RA without feeling bad, 
taking RA medication without feeling being hassled). cOnclusiOns: The results 
of this study suggest that RA patients’ care needs are multidimensional and time 
sensitive. A muti-pronged approach including drug therapy, and patient education, 
support, and counselling is needed from start of treatment to help patients form 
the new normality of their lives.
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suitaBility research on the evaluation of eq-5q anD sf-6D scale for 
the quality of life in Patients With osteoarthritis
Fang Z
Shenyang Pharmaceutical University, Shenyang, China
Objectives: As the universal scales, EQ-5D and SF-6D have been widely used 
in the evaluation of the quality of life(QOL) of patients with many kinds of dis-
ease including Osteoarthritis. But as to which scale is much more suitable for the 
Osteoarthritis patients evaluation , there is scarcely any research so far. The cur-
rent study aimed to compare the correlation of the EQ -5D, SF-6D with AIMS2-2F 
scale, the specificity scale of QOL evaluation, then to determine the suitability of 
two scale for the QOL of patients with Osteoarthritis. MethOds: From April to 
December in 2012, 100 patients with Osteoarthritis were enrolled with consent 
at Orthopedic Clinic in the First Affiliated Hospital of Chinese Medical University. 
They filled out the EQ-5D, SF-6D, and AIMS2 2F scales successively by themselves 
. SPSS19.0 analysis software was used to deal with the collected data, parts of the 
lack data were eliminated automatically . Cronbach alpha coefficient evaluated 
the internal consistency of scales. Pearson, Speaman and Kendall’s tau-b correla-
tion coefficient analysis were used to test the reliability between EQ-5D, SF-6D 
and AIMS2-2F score data. On the scale of the response and the factors affecting 
the QOL, we use multiple stepwise regression analysis, significant test of bilat-
eral boundary value point. Results: 77 sets of valid survey scale were analyst 
EQ-5D, SF-6D, and AIMS2-2F scales all had good internal consistency showing good 
reliability with the crowns Bach coefficient were all higher than 0.6.During the 
various dimensions of EQ-5D scale, Anxiety, Pain, Daily life and Self care showed 
the higher sensitivity on AIMS2-2F scale. Followed by Ability to act . As to SF-6D 
scale, Psychological health, Vitality, and Social function showed higher sensitiv-
ity on AIMS2-2F scale. And followed by Role constraints, Pain and Physical func-
